Table 4 Characteristics of the patients with MTX concentrations below the adherence limit
Patient | Sex | Age (y) | Time after start MTX (days) | Dose (mg) | Form | Biological | Information JAMAR (child) |
|---|---|---|---|---|---|---|---|
Baseline | |||||||
1* | M | 13 | 42 | 7.5 | Tablet | None | No data |
2** | F | 17 | 63 | 20 | Tablet | None | Adherent |
3*** | M | 15 | 91 | 20 | Tablet | None | Adherent |
4 | M | 14 | 62 | 15 | Tablet | None | No data |
5 | F | 16 | 70 | 20 | Tablet | None | No data |
Follow up | |||||||
1* | M | 13 | 343 | 7.5 | Tablet | Adalimumab | Non-adherent |
2** | F | 17 | 378 | 20 | Tablet | None | Adherent |
3*** | M | 15 | 383 | 20 | Tablet | None | Non-adherent |
4 | F | 16 | 357 | 20 | Tablet | None | Adherent |
5 | F | 13 | 273 | 12.5 | Tablet | None | No data |
6 | F | 11 | 315 | 10 | Tablet | Etanercept | No data |
7 | F | 8 | 389 | 10 | Tablet | None | No data |
8 | M | 13 | 349 | 15 | Tablet | None | Adherent |
9 | M | 11 | 427 | 12.5 | Tablet | None | No data |
10 | F | 14 | 294 | 20 | Tablet | None | Adherent |